Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00139373 |
Date of registration:
|
30/08/2005 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy
|
Scientific title:
|
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy |
Date of first enrolment:
|
May 2005 |
Target sample size:
|
16 |
Recruitment status: |
Recruiting |
URL:
|
http://clinicaltrials.gov/show/NCT00139373 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
Phase:
|
Phase 2
|
|
Countries of recruitment
|
France
| | | | | | | |
Contacts
|
Name:
|
Bertrand Gaymard, MD, PhD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
INSERM-U679 |
|
Name:
|
Marie-Laure Welter, MD |
Address:
|
|
Telephone:
|
33-42161950 |
Email:
|
marie-laure.welter@psl.aphp.fr |
Affiliation:
|
|
|
Name:
|
Bertrand Gaymard, MD, PhD |
Address:
|
|
Telephone:
|
33-142162218 |
Email:
|
gaymard@ccr.jussieu.fr |
Affiliation:
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients with PSP
- Age > 30 years old
- Disease duration < 5 years
- Mini mental state (MMS) > 24
- Antisaccades %: 40-80%
Exclusion Criteria:
- Other parkinsonian syndromes
- MMS < 24
Age minimum:
30 Years
Age maximum:
80 Years
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Supranuclear Palsy, Progressive
|
Intervention(s)
|
Drug: donepezil
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|